Sumitomo Dainippon Pharma Annual Report 2017
97/102

6) Information on impairment loss of non-current assets, amortization and unamortized balance of goodwill by reportable segmentMillions of yenJapanNorth AmericaChinaOther RegionsSubtotalOther BusinessTotal¥ — — —¥ — 5,560 90,565 ¥ — — —¥ — — —¥ — 5,560 90,565¥ — — —¥ —5,560 90,56520172017Impairment loss Amortization of goodwill Balance of goodwillMillions of yenJapanNorth AmericaChinaOther RegionsSubtotalOther BusinessTotal¥ 33 — —¥ 2635,98076,950 ¥ — — —¥ — — —¥ 2965,98076,950¥ 257 — —¥ 5535,98076,9502016Impairment loss Amortization of goodwill Balance of goodwillThousands of U.S. dollarsJapanNorth AmericaChinaOther RegionsSubtotalOther BusinessTotal$ — — —$ —49,643808,616 $ — — —$ — — —$ —49,643808,616$ — — —$ —49,643808,616Impairment loss Amortization of goodwill Balance of goodwill2016LocationMillions of yen ¥ 257 152 33Production facilitiesJapanU.S.AJapanBuildings and structures, etc.Research and development with respect to compound in developmentIn-process research and developmentIdle assetsMachinery, equipment andcarriers etc.111U.S.ASales facilitiesConstruction in progress for softwareUsage forItemImpairment loss of tangible assets and intangible assets for the years ended March 31, 2016 was as follows:One of the subsidiaries impaired the book value of its production facilities after measuring the recoverable amount based on value-in-use since the subsidiary has booked operating losses continuously. In addition, the Company and its consolidated subsidiaries impaired the book value of idle tangible assets, as well as in-process research and development costs and intangible assets (Construction in progress for software) of which future economic benets were expected to be less than the book value. The recoverable amount of intangible assets (Construction in progress for software) and idle tangible assets was measured based on value-in-use, which was determined as zero. The recoverable amount of in-process research and development costs was measured based on value-in-use using a discount rate of 8.0%.17. IMPAIRMENT LOSSSumitomo Dainippon Pharma Co., Ltd. Annual Report 201796

元のページ  ../index.html#97

このブックを見る